Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)

DSpace Repository

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)

Author: von Minckwitz, G.; Loibl, S.; Untch, M.; Eidtmann, H.; Rezai, M.; Fasching, P. A.; Tesch, H.; Eggemann, H.; Schrader, I.; Kittel, K.; Hanusch, C.; Huober, J.; Solbach, C.; Jackisch, C.; Kunz, G.; Blohmer, J. U.; Hauschild, M.; Fehm, T.; Nekljudova, V.; Gerber, B.
Tübinger Autor(en):
Fehm, Tanja
Published in: Annals of Oncology (2014), Bd. 25, H. 12, S. 2363-2372
Verlagsangabe: Oxford Univ Press
Language: English
Full text: http://dx.doi.org/10.1093/annonc/mdu455
ISSN: 0923-7534
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)